Cargando…
Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
The objective of the current work was to demonstrate the equivalence of Mylan’s glatiramer acetate (GA) to that of the reference product Copaxone(®) (COP) using the four criteria for active pharmaceutical ingredient sameness as established by the US Food and Drug Administration (FDA). The reaction s...
Autores principales: | Lipsky, Peter, Vallano, Patrick T., Smith, Jeffrey, Owens, Walter, Snider, Daniel, Bandaru, Viswanath, Sun, Yunfu, Wallingford, Ross, Duncan, Joseph, Lewis, Joshua, Southall, Jason, Ansari, Azeem, Li, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740218/ https://www.ncbi.nlm.nih.gov/pubmed/35002702 http://dx.doi.org/10.3389/fphar.2021.760726 |
Ejemplares similares
-
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017) -
Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone
por: Melamed-Gal, S., et al.
Publicado: (2018) -
Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use
por: Wynn, Daniel R.
Publicado: (2019) -
Glatiramer Acetate (Copaxone) Modulates Platelet Activation and Inhibits Thrombin-Induced Calcium Influx: Possible Role of Copaxone in Targeting Platelets during Autoimmune Neuroinflammation
por: Starossom, Sarah C., et al.
Publicado: (2014) -
Assessing the In Vitro Potential of Glatiramer Acetate (Copaxone(®)) as a Chemotherapeutic Candidate for the Treatment of Cryptococcus neoformans Infection
por: Alves, Vinicius, et al.
Publicado: (2023)